Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

  • STATUS
    Recruiting
  • participants needed
    25
  • sponsor
    Jennifer Woyach
Updated on 29 January 2022
fever
cancer
corticosteroids
lymphoid leukemia
anemia
chronic lymphocytic leukemia
monoclonal antibodies
fatigue
thrombocytopenia
neutrophil count
monoclonal protein
beta human chorionic gonadotrophin
ibrutinib
lymphadenopathy
night sweats
hepatitis b core antibody
constitutional symptoms

Summary

This phase Ib trials studies the side effects of daratumumab and ibrutinib and how well they work in treating patients with symptomatic chronic lymphocytic leukemia. Monoclonal antibodies, such as daratumumab, may interfere with the ability of cancer cells to grow and spread. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving daratumumab and ibrutinib may work better in treating patients with chronic lymphocytic leukemia.

Description

PRIMARY OBJECTIVES:

I. To characterize the safety of treatment with daratumumab and ibrutinib for previously untreated chronic lymphocytic leukemia (CLL).

II. To determine the complete response rate (CR) at the post cycle 12 response assessment following treatment with daratumumab and ibrutinib for previously untreated chronic lymphocytic leukemia (CLL).

SECONDARY OBJECTIVES:

I. To characterize the activity of daratumumab and ibrutinib as measured by overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and time-to-next treatment.

TERTIARY OBJECTIVES:

I. To measure pharmacodynamic parameters in B cells including drug occupancy of BTK and B cell receptor signaling during treatment.

II. To determine the influence of this combination on T cell and natural killer (NK) cell number and function.

III. To assess for development of mutations that may confer resistance to this combination.

IV. To assess the ability of daratumumab to clear CLL in the peripheral blood and association of CD38 expression on CLL cells with response.

OUTLINE

Patients receive daratumumab intravenously (IV) on days 1, 8, 15, and 22 of courses 1-2, days 1 and 15 of courses 3-6, and day 1 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Beginning course 2, patients also receive ibrutinib orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 12 weeks for up to 2 years.

Details
Condition leukemia chronic lymphocytic, small lymphocytic lymphoma, Lymphocytic Leukemia, Chronic, chronic lymphocytic leukemia (cll), Chronic Lymphocytic Leukemia
Treatment laboratory biomarker analysis, Ibrutinib, pharmacological study, Daratumumab
Clinical Study IdentifierNCT03447808
SponsorJennifer Woyach
Last Modified on29 January 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note